# Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine

- Source: PR Newswire M&A
- Published: 2026-11-06T02:27:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/phase-ii-study-of-ivonescimab-in-the-perioperative-setting-for-resectable-nsclc-published-in-nature-medicine-302931595.html
- Canonical: https://groundlevelnews.com/story/phase-ii-study-of-ivonescimab-in-the-perioperative-setting-for-resecta-bd26fd/

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resectable non-small cell lung cancer (NSCLC) have been...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._